Therapeutic area intelligence for Urothelial Cancer with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Gemcitabine →

pembrolizumab →

Recent signals(2)

ClinicalAugust 12, 2026

Phase III Trial of Pembrolizumab and Sacituzumab Govitecan-hziy in Advanced Urothelial Cancer

A phase III trial is underway comparing pembrolizumab and sacituzumab govitecan-hziy against standard chemotherapy for advanced urothelial cancer.

ClinicalJuly 14, 2026

NCI Study Evaluates Gemcitabine, Carboplatin, and Lenalidomide for Urothelial Cancer

A clinical trial is assessing the safety and efficacy of a combination of gemcitabine, carboplatin, and lenalidomide for treating advanced urothelial cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Urothelial Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.